Highly variable cost-effectiveness with disease characteristics and age: Herceptin as a Case Study

Tuesday, October 25th, 2016 | Kate Sloane | 3 Comments

Prof Tony Blakely, Dr Nisha Nair

Herceptin blog imageThis blog is, and isn’t, about the breast cancer drug Herceptin. It is about Herceptin in that we report on a study we just published in the journal PLoS Medicine about the health gains, costs, and cost-effectiveness of Herceptin. It isn’t about Herceptin in that the key point is far more general: in the age of personalised and precision medicine, our country’s funding decisions are often blunt and imprecise, some may even say wasteful. We raise some hard and contentious issues – but talking about money and health in the same breath always is.

Continue reading